Wathsala Liyanage

Wathsala Liyanage

Auto-generated profile, based on publicly available information

Wathsala Liyanage

Johns Hopkins University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
WLWathsala Liyanage
Wathsala Liyanage
TWTony Wu
Tony Wu
SKSujatha Kannan
Sujatha Kannan
Kannan RangaramanujamKannan Rangaramanujam
Kannan Rangaramanujam


30 September 2020 in Soft Matter
Verified
Journal Article
Closed access
PDF file
EQElena Quigley
Elena Quigley
JJJade Johnson
Jade Johnson
WLWathsala Liyanage
Wathsala Liyanage
BNBradley Nilsson
Bradley Nilsson
Supramolecular hydrogels formed by noncovalent self-assembly of low molecular weight (LMW) agents are promising next-generation biomaterials.

19 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
RNRajiv Ranjit Nair
Rajiv Ranjit Nair
ASAira Sarkar
Aira Sarkar
PHPooja Hariharan
Pooja Hariharan
KGKathleen L. Gabrielson
Kathleen L. Gabrielson
TWTony Wu
Tony Wu
ASAnjali Sharma
Anjali Sharma
RATIONALE: The poor prognosis of glioblastoma is largely due to drug resistance and tumor location that, together, make it difficult to treat aggressively without affecting the rest of the brain. METHODOLOGY: High-energy, short-range (40-80µm) dendrimer-delivered α-particles could address both challenges, because (1) they cause complex, highly cytotoxic double-strand DNA breaks, and (2) irradiation of the neighboring brain is minimal, since dendrimers selectively delivers them to tumors. Since cancer cells that are not directly hit by α-particles will likely not be killed, the patterns of tumor irradiation affect efficacy. Systemically injected dendrimers extensively accumulate in glioblastomas, where they are taken up by tumor associated macrophages (TAMs), which tend to infiltrate tumors. We hypothesized that dendrimers labeled with α-particle emitters, when being carried by TAMs, could more evenly irradiate glioblastomas, improving survival. In this study, the efficacy of dendrimers radiolabeled with the α-particle emitter actinium-225 (dendrimer-radioconjugates) was evaluated when administered alone and/or after temozolomide, in a syngeneic immune-competent orthotopic GL261-C57BL/6 mouse model. RESULTS: Systemically-administered dendrimer-radioconjugates, at activities that did not result in long-term toxicities, prolonged survival of mice with orthotopic GL261 tumors, compared to standard-of-care temozolomide (39 vs 31 days mean survival, p=0.0061) and non-treated animals (30 days, p=0.0009). Importantly, injection of temozolomide 24 hours before administration of dendrimer-radioconjugates further improved survival remarkably (44 days). This improvement in efficacy was attributed to: (1) the significant increase (by 33%) in tumor absorbed doses delivered by dendrimer-radioconjugates when injected after chemotherapy, without altering normal organ dosimetry, while sparing the tumor-surrounding healthy brain; (2) the potentially deeper tumor penetration of dendrimer-radioconjugates, suggested by the enhancement of dendrimer penetration within GL261-spheroids, employed as model tumor-avascular regions and/or TAM-free regions; and/or (3) the formation of a more lethal cocktail when both modalities acted on same cancer cells, that was correlated with increased levels of dendrimer-radioconjugates associating with GL261 cells in vitro and with greater incidences of karyomegaly in vivo . CONCLUSIONS: This study demonstrates the potential of a ‘brain tumor targeted’ systemic actinium-225 radiopharmaceutical therapy that inhibits growth of glioblastoma cells and prolongs survival of mice with orthotopic brain tumors, further improved by standard-of-care temozolomide, without notable toxicities.

27 August 2025 in bioRxiv
Verified
Preprint
Open access
PHPooja Hariharan
Pooja Hariharan
RNRajiv Nair
Rajiv Nair
ASAira Sarkar
Aira Sarkar
KGKathleen L. Gabrielson
Kathleen L. Gabrielson
TWTony Wu
Tony Wu
SSStavroula Sofou
Stavroula Sofou
PURPOSE: Metastatic triple negative breast cancer (mTNBC) is incurable largely due to the development of drug resistance, the lack of selective cell targeting, and/or limitations in tumor drug delivery that vary depending on the different (metastatic) tumor locations. METHODS: The potential of a single type of systemic, targeted alpha-particle therapy (TAT) was investigated for addressing the above challenges of TNBC tumors implanted at different anatomic sites in mice. Actinium-225 dendrimer-radioconjugates alone, and/or after pretreatment with low-dose standard-of-care cisplatin, were assessed in vitro and on immune-competent 4T1-Balb/c mouse models with tumors implanted intracranially, orthotopically or subcutaneously. RESULTS: In vitro , TAT’s efficacy was enhanced by cisplatin . In vivo , treatment was initiated well after tumors had grown (V to = 39 ± 14 mm 3 in the intracranial model, and V to =100mm 3 in the orthotopic and subcutaneous models). Across all tumor implantation sites, a unified correlation was observed between animal mean survival and the dendrimer-delivered tumor absorbed doses, which were selectively increased by low-dose cisplatin pretreatment . Importantly, in all animal models, the mean survival following systemic treatment with both modalities was significantly longer vs. each modality alone and/or vs. no treatment, at injected doses that did not cause long-term (10-month) toxicities in tumor-free mice. CONCLUSION: Systemically-injected dendrimer-delivered TAT, combined with low-dose cisplatin pretreatment , can safely extend survival independent of mTNBC tumors’ anatomic site, potentially presenting a single type of therapy to simultaneously treat multi-site mTNBC.